Elena Garcia-Martin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6268692/publications.pdf

Version: 2024-02-01

231	6,345	66234	114278
papers	citations	42 h-index	63 g-index

236	236	236	6798
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Serum Trace Elements Concentrations in Patients with Restless Legs Syndrome. Antioxidants, 2022, 11, 272.	2.2	7
2	Association of Essential Tremor With Novel Risk Loci. JAMA Neurology, 2022, 79, 185.	4.5	17
3	Increased serum diamine oxidase activity in nonallergic patients with migraine. European Journal of Clinical Investigation, 2022, 52, e13757.	1.7	10
4	Vitamin D Receptor and Binding Protein Gene Variants in Patients with Essential Tremor. Molecular Neurobiology, 2022, , 1.	1.9	0
5	Editorial: Insights in Pharmacogenetics and Pharmacogenomics: 2021. Frontiers in Pharmacology, 2022, 13, 907131.	1.6	1
6	Common UGT1A6 Variant Alleles Determine Acetaminophen Pharmacokinetics in Man. Journal of Personalized Medicine, 2022, 12, 720.	1.1	2
7	Molecular monitoring of patient response to painkiller drugs. Expert Review of Molecular Diagnostics, 2022, 22, 545-558.	1.5	0
8	Cerebrospinal and blood levels of amino acids as potential biomarkers for Parkinson's disease: review and metaâ€analysis. Response to letter to the editor by Zheng et al.. European Journal of Neurology, 2021, 28, e13-e14.	1.7	2
9	Serum vitamin D, vitamin D receptor and binding protein genes polymorphisms in restless legs syndrome. Journal of Neurology, 2021, 268, 1461-1472.	1.8	7
10	Exome-wide rare variant analysis in familial essential tremor. Parkinsonism and Related Disorders, 2021, 82, 109-116.	1.1	11
11	Biological fluid levels of iron and ironâ€related proteins in Parkinsonâ€™s disease: Review and metaâ€analysis. European Journal of Neurology, 2021, 28, 1041-1055.	1.7	15
12	Common Endothelial Nitric Oxide Synthase Single Nucleotide Polymorphisms are not Related With the Risk for Restless Legs Syndrome. Frontiers in Pharmacology, 2021, 12, 618989.	1.6	3
13	Variability of the Genes Involved in the Cellular Redox Status and Their Implication in Drug Hypersensitivity Reactions. Antioxidants, 2021, 10, 294.	2.2	4
14	Deep sequencing of prostaglandinâ€endoperoxide synthase (PTGE) genes reveals genetic susceptibility for crossâ€reactive hypersensitivity to NSAID. British Journal of Pharmacology, 2021, 178, 1218-1233.	2.7	7
15	Sleep Disorders in Patients with Essential Tremor. Current Neurology and Neuroscience Reports, 2021, 21, 23.	2.0	5
16	Association between restless legs syndrome and peripheral neuropathy: A systematic review and metaâ€analysis. European Journal of Neurology, 2021, 28, 2423-2442.	1.7	14
17	Genomic Markers for Essential Tremor. Pharmaceuticals, 2021, 14, 516.	1.7	16
18	Genetic Variants of Alcohol Metabolizing Enzymes and Alcohol-Related Liver Cirrhosis Risk. Journal of Personalized Medicine, 2021, 11, 409.	1.1	1

#	Article	IF	Citations
19	Neurochemical Features of Rem Sleep Behaviour Disorder. Journal of Personalized Medicine, 2021, 11, 880.	1.1	10
20	Lack of Major Involvement of Common CYP2C Gene Polymorphisms in the Risk of Developing Cross-Hypersensitivity to NSAIDs. Frontiers in Pharmacology, 2021, 12, 648262.	1.6	0
21	Current Treatment Options for REM Sleep Behaviour Disorder. Journal of Personalized Medicine, 2021, 11, 1204.	1.1	6
22	Editorial: NSAIDs Pharmacogenomics. Frontiers in Pharmacology, 2021, 12, 798447.	1.6	1
23	Association between endothelial nitric oxide synthase (NOS3) rs2070744 and the risk for migraine. Pharmacogenomics Journal, 2020, 20, 426-432.	0.9	12
24	Outcomes and Laboratory and Clinical Findings of Asthma and Allergic Patients Admitted With Covid-19 in a Spanish University Hospital. Frontiers in Pharmacology, 2020, 11, 570721.	1.6	5
25	Anti-Inflammatory Effects of Amantadine and Memantine: Possible Therapeutics for the Treatment of Covid-19?. Journal of Personalized Medicine, 2020, 10, 217.	1.1	25
26	Cerebrospinal and blood levels of amino acids as potential biomarkers for Parkinsonâ€™s disease: review and metaâ€analysis. European Journal of Neurology, 2020, 27, 2336-2347.	1.7	26
27	Modulation of CYP2C9 activity and hydrogen peroxide production by cytochrome b5. Scientific Reports, 2020, 10, 15571.	1.6	13
28	Endothelial nitric oxide synthase (NOS3) rs2070744 polymorphism and risk for multiple sclerosis. Journal of Neural Transmission, 2020, 127, 1167-1175.	1.4	6
29	An update on the pharmacogenomics of NSAID metabolism and the risk of gastrointestinal bleeding. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 319-332.	1.5	18
30	Sleep disorders in essential tremor: systematic review and meta-analysis. Sleep, 2020, 43, .	0.6	15
31	Photomutagenicity of chlorpromazine and its N-demethylated metabolites assessed by NGS. Scientific Reports, 2020, 10, 6879.	1.6	7
32	Sleep disorders in tourette syndrome. Sleep Medicine Reviews, 2020, 53, 101335.	3.8	25
33	An Update on the Neurochemistry of Essential Tremor. Current Medicinal Chemistry, 2020, 27, 1690-1710.	1.2	8
34	Current and Future Neuropharmacological Options for the Treatment of Essential Tremor. Current Neuropharmacology, 2020, 18, 518-537.	1.4	20
35	Polymorphisms in CEP68 gene associated with risk of immediate selective reactions to non-steroidal anti-inflammatory drugs. Pharmacogenomics Journal, 2019, 19, 191-199.	0.9	12
36	Identification of Novel Biomarkers for Drug Hypersensitivity After Sequencing of the Promoter Area in 16 Genes of the Vitamin D Pathway and the High-Affinity IgE Receptor. Frontiers in Genetics, 2019, 10, 582.	1.1	10

#	Article	IF	Citations
37	NSAID-induced reactions: classification, prevalence, impact, and management strategies . Journal of Asthma and Allergy, 2019, Volume 12, 217-233.	1.5	43
38	Pharmacogenetic Factors Affecting Asthma Treatment Response. Potential Implications for Drug Therapy. Frontiers in Pharmacology, 2019, 10, 520.	1.6	31
39	Association Study Among Candidate Genetic Polymorphisms and Chemotherapy-Related Severe Toxicity in Testicular Cancer Patients. Frontiers in Pharmacology, 2019, 10, 206.	1.6	8
40	Association between restless legs syndrome and other movement disorders. Neurology, 2019, 92, 948-964.	1.5	45
41	Neurochemical features of idiopathic restless legs syndrome. Sleep Medicine Reviews, 2019, 45, 70-87.	3.8	31
42	Next-Generation Sequencing of PTGS Genes Reveals an Increased Frequency of Non-synonymous Variants Among Patients With NSAID-Induced Liver Injury. Frontiers in Genetics, 2019, 10, 134.	1.1	10
43	The role of phase I and II genetic polymorphisms, smoking, alcohol and cancer family history, in the risk of developing testicular cancer. Pharmacogenetics and Genomics, 2019, 29, 159-166.	0.7	9
44	Alcohol consumption and risk for Parkinsonâ€™s disease: a systematic review and meta-analysis. Journal of Neurology, 2019, 266, 1821-1834.	1.8	27
45	Association between the missense alcohol dehydrogenase rs1229984T variant with the risk for Parkinsonâ€™s disease in women. Journal of Neurology, 2019, 266, 346-352.	1.8	14
46	Gamma-aminobutyric acid (GABA) receptors GABRA4, GABRE, and GABRQ gene polymorphisms and risk for migraine. Journal of Neural Transmission, 2018, 125, 689-698.	1.4	14
47	Gamma-aminobutyric acid (GABA) receptors genes polymorphisms and risk for restless legs syndrome. Pharmacogenomics Journal, 2018, 18, 565-577.	0.9	18
48	Acetyl Salicylic Acid Challenge in Children with Hypersensitivity Reactions to Nonsteroidal Anti-Inflammatory Drugs Differentiates Between Cross-Intolerant and Selective Responders. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1226-1235.	2.0	30
49	Genetics of restless legs syndrome: An update. Sleep Medicine Reviews, 2018, 39, 108-121.	3.8	78
50	NSAIDs-hypersensitivity often induces a blended reaction pattern involving multiple organs. Scientific Reports, 2018, 8, 16710.	1.6	36
51	The potential role of pharmacogenomics and biotransformation in hypersensitivity reactions to paracetamol. Current Opinion in Allergy and Clinical Immunology, 2018, 18, 302-309.	1.1	7
52	Missense Gamma-Aminobutyric Acid Receptor Polymorphisms Are Associated with Reaction Time, Motor Time, and Ethanol Effects in Vivo. Frontiers in Cellular Neuroscience, 2018, 12, 10.	1.8	6
53	Asthma and allergic rhinitis associate with the rs2229542 variant that induces a p.Lys90Glu mutation and compromises AKR1B1 protein levels. Human Mutation, 2018, 39, 1081-1091.	1.1	4
54	Hypersensitivity reactions to nonsteroidal anti-inflammatory drugs: an update on pharmacogenetics studies. Pharmacogenomics, 2018, 19, 1069-1086.	0.6	13

#	Article	IF	Citations
55	Human Arylamine N-Acetyltransferase Type 2: Phenotypic Correlation with Genotype-A Clinical Perspective. , 2018, , 69-89.		6
56	Deltaâ€aminoâ€levulinic acid dehydratase gene and essential tremor. European Journal of Clinical Investigation, 2017, 47, 348-356.	1.7	4
57	Gammaâ€Aminobutyric Acid (Gaba) Receptors Rho (Gabrr) Gene Polymorphisms and Risk for Migraine. Headache, 2017, 57, 1118-1135.	1.8	15
58	Thr105Ile (rs11558538) polymorphism in the histamine-1-methyl-transferase (HNMT) gene and risk for restless legs syndrome. Journal of Neural Transmission, 2017, 124, 285-291.	1.4	14
59	Association Between the rs1229984 Polymorphism in the Alcohol Dehydrogenase 1B Gene and Risk for Restless Legs Syndrome. Sleep, 2017, 40, .	0.6	14
60	Editorial: Biomarkers in Drug Hypersensitivity. Frontiers in Pharmacology, 2017, 8, 348.	1.6	0
61	Update on the Genetic Basis of Drug Hypersensitivity Reactions. Journal of Investigational Allergology and Clinical Immunology, 2017, 27, 336-345.	0.6	17
62	The Genetics of Drug Hypersensitivity Reactions. Journal of Investigational Allergology and Clinical Immunology, 2016, 26, 222-232.	0.6	5
63	Asthma and Rhinitis Induced by Selective Immediate Reactions to Paracetamol and Non-steroidal Anti-inflammatory Drugs in Aspirin Tolerant Subjects. Frontiers in Pharmacology, 2016, 7, 215.	1.6	16
64	Detoxifying Enzymes at the Cross-Roads of Inflammation, Oxidative Stress, and Drug Hypersensitivity: Role of Glutathione Transferase P1-1 and Aldose Reductase. Frontiers in Pharmacology, 2016, 7, 237.	1.6	31
65	Pharmacogenomics of Prostaglandin and Leukotriene Receptors. Frontiers in Pharmacology, 2016, 7, 316.	1.6	32
66	FCERI and Histamine Metabolism Gene Variability in Selective Responders to NSAIDS. Frontiers in Pharmacology, 2016, 7, 353.	1.6	22
67	Copy number variation in ALOX5 and PTGER1 is associated with NSAIDs-induced urticaria and/or angioedema. Pharmacogenetics and Genomics, 2016, 26, 280-287.	0.7	15
68	GC Gene Polymorphism and Unbound Serum Retinol-Binding Protein 4 Are Related to the Risk of Insulin Resistance in Patients With Chronic Hepatitis C. Medicine (United States), 2016, 95, e3019.	0.4	13
69	A Nonsynonymous FCER1B SNP is Associated with Risk of Developing Allergic Rhinitis and with IgE Levels. Scientific Reports, 2016, 6, 19724.	1.6	14
70	Advances in understanding genomic markers and pharmacogenetics of Parkinsonâ€™s disease. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 433-448.	1.5	33
71	A family study of DRD3 rs6280, SLC1A2 rs3794087 and MAPT rs1052553 variants in essential tremor. Neurological Research, 2016, 38, 880-887.	0.6	8
72	7th Drug hypersensitivity meeting: part two. Clinical and Translational Allergy, 2016, 6, .	1.4	0

#	Article	IF	Citations
73	Heme Oxygenase-1 and 2 Common Genetic Variants and Risk for Multiple Sclerosis. Scientific Reports, 2016, 6, 20830.	1.6	26
74	Pyrazolones metabolites are relevant for identifying selective anaphylaxis to metamizole. Scientific Reports, 2016, 6, 23845.	1.6	44
75	Thr105Ile (rs11558538) polymorphism in the histamine N-methyltransferase (HNMT) gene and risk for Parkinson disease. Medicine (United States), 2016, 95, e4147.	0.4	19
76	Allergic Reactions to Metamizole: Immediate and Delayed Responses. International Archives of Allergy and Immunology, 2016, 169, 223-230.	0.9	37
77	NAT2 polymorphisms and risk for Parkinsonâ€™s disease: a systematic review and meta-analysis. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 937-946.	1.5	6
78	Immediate hypersensitivity reactions to ibuprofen and other arylpropionic acid derivatives. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 1048-1056.	2.7	19
79	Molecular Interactions and Implications of Aldose Reductase Inhibition by PGA₁ and Clinically Used Prostaglandins. Molecular Pharmacology, 2016, 89, 42-52.	1.0	16
80	An Update on the Role of Nitric Oxide in the Neurodegenerative Processes of Parkinson's Disease. Current Medicinal Chemistry, 2016, 23, 2666-2679.	1.2	51
81	Measuring Hemoglobin Levels in the Optic Nerve Head for Glaucoma Management. , 2016, , 265-280.		3
82	Genetic determinants of metamizole metabolism modify the risk of developing anaphylaxis. Pharmacogenetics and Genomics, 2015, 25, 462-464.	0.7	25
83	Neuronal Nitric Oxide Synthase (<scp>nNOS</scp>, <scp>NOS</scp>1) rs693534 and rs7977109 Variants and Risk for Migraine. Headache, 2015, 55, 1209-1217.	1.8	18
84	Genetic basis of hypersensitivity reactions to nonsteroidal anti-inflammatory drugs. Current Opinion in Allergy and Clinical Immunology, 2015, 15, 285-293.	1.1	11
85	Association Between Vitamin D Receptor rs731236 (Taq1) Polymorphism and Risk for Restless Legs Syndrome in the Spanish Caucasian Population. Medicine (United States), 2015, 94, e2125.	0.4	23
86	Drug metabolism and hypersensitivity reactions to drugs. Current Opinion in Allergy and Clinical Immunology, 2015, 15, 277-284.	1.1	8
87	Editorial on Cerebral endothelial and glial cells are more than bricks in the Great Wall of the brain: insights into the way the blood-brain barrier actually works (celebrating the centenary of Goldman's) Tj ETQq1 1 0.784314 rgBT /Over		
88	Pharmacogenomics of cyclooxygenases. Pharmacogenomics, 2015, 16, 501-522.	0.6	43
89	Heme Oxygenase 1 and 2 Common Genetic Variants and Risk for Essential Tremor. Medicine (United) Tj ETQq1 1 0.784314 rgBT /Ove	0.4	20
90	Heme Oxygenase-1 and 2 Common Genetic Variants and Risk for Restless Legs Syndrome. Medicine (United States), 2015, 94, e1448.	0.4	31

#	Article	IF	Citations
91	Neuronal nitric oxide synthase (nNOS, NOS1) rs693534 and rs7977109 variants and risk for restless legs syndrome. Journal of Neural Transmission, 2015, 122, 819-823.	1.4	23
92	Diamine Oxidaseâ€...<scp>rs</scp>10156191 and <scp>rs</scp>2052129 Variants Are Associated With the Risk for Migraine. Headache, 2015, 55, 276-286.	1.8	49
93	Missense mutations inTENM4, a regulator of axon guidance and central myelination, cause essential tremor. Human Molecular Genetics, 2015, 24, 5677-5686.	1.4	134
94	TREM2 R47H variant and risk of essential tremor: A cross-sectional international multicenter study. Parkinsonism and Related Disorders, 2015, 21, 306-309.	1.1	28
95	The potential of LINGO-1 as a therapeutic target for essential tremor. Expert Opinion on Therapeutic Targets, 2015, 19, 1139-1148.	1.5	9
96	Analysis of optic disk color changes in Alzheimer's disease: A potential new biomarker. Clinical Neurology and Neurosurgery, 2015, 132, 68-73.	0.6	37
97	The GSTP1 gene variant rs1695 is not associated with an increased risk of multiple sclerosis. Cellular and Molecular Immunology, 2015, 12, 777-779.	4.8	5
98	SLC1A2 rs3794087 variant and risk for essential tremor. Pharmacogenetics and Genomics, 2015, 25, 564-568.	0.7	11
99	Neurochemistry of Idiopathic Restless Legs Syndrome. European Neurological Review, 2015, 10, 35.	0.5	7
100	Treatment Options for Idiopathic Restless Legs Syndrome. European Neurological Review, 2015, 10, 45.	0.5	2
101	Variants of CEP68 Gene Are Associated with Acute Urticaria/Angioedema Induced by Multiple Non-Steroidal Anti-Inflammatory Drugs. PLoS ONE, 2014, 9, e90966.	1.1	17
102	Measuring Hemoglobin Levels in the Optic Disc of Parkinsonâ€™s Disease Patients Using New Colorimetric Analysis Software. Parkinson's Disease, 2014, 2014, 1-8.	0.6	7
103	An association study between Heme oxygenase-1 genetic variants and Parkinson's disease. Frontiers in Cellular Neuroscience, 2014, 8, 298.	1.8	39
104	Drug and xenobiotic biotransformation in the bloodÃ¢â‚¬â€œbrain barrier: a neglected issue. Frontiers in Cellular Neuroscience, 2014, 8, 335.	1.8	37
105	Clinical practice guidelines for translating pharmacogenomic knowledge to bedside. Focus on anticancer drugs. Frontiers in Pharmacology, 2014, 5, 188.	1.6	5
106	COMT gene and risk for Parkinsonâ€™s disease. Pharmacogenetics and Genomics, 2014, 24, 331-339.	0.7	33
107	Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease. Frontiers in Cellular Neuroscience, 2014, 8, 369.	1.8	68
108	<i>PITX3</i> and Risk for Parkinson's Disease: A Systematic Review and Meta-Analysis. European Neurology, 2014, 71, 49-56.	0.6	16

#	Article	IF	Citations
109	The solute carrier family 1 (glial high affinity glutamate transporter), member 2 gene, SLC1A2, rs3794087 variant and assessment risk for restless legs syndrome. Sleep Medicine, 2014, 15, 266-268.	0.8	22
110	SLC1A2 rs3794087 variant and risk for migraine. Journal of the Neurological Sciences, 2014, 338, 92-95.	0.3	13
111	Evaluation of immediate allergic reactions to dipyrone using dipyrone metabolites in basophil activation test. Clinical and Translational Allergy, 2014, 4, P33.	1.4	0
112	NQO1gene rs1800566 variant is not associated with risk for multiple sclerosis. BMC Neurology, 2014, 14, 87.	0.8	10
113	Gender and functional CYP2C and NAT2 polymorphisms determine the metabolic profile of metamizole. Biochemical Pharmacology, 2014, 92, 457-466.	2.0	26
114	Genomic and Pharmacogenomic Biomarkers of Parkinsonâ€™s Disease. Current Drug Metabolism, 2014, 15, 129-181.	0.7	47
115	Gene Variants and Haplotypes Modifying Transcription Factor Binding Sites in the Human Cyclooxygenase 1 and 2 (PTGS1 and PTGS2) Genes. Current Drug Metabolism, 2014, 15, 182-195.	0.7	26
116	Perception of the Usefulness of Drug/Gene Pairs and Barriers for Pharmacogenomics in Latin America. Current Drug Metabolism, 2014, 15, 202-208.	0.7	31
117	LINGO1 rs9652490 and rs11856808 polymorphisms are not associated with risk for multiple sclerosis. BMC Neurology, 2013, 13, 34.	0.8	10
118	MAPT1 gene rs1052553 variant is unrelated with the risk for restless legs syndrome. Journal of Neural Transmission, 2013, 120, 463-467.	1.4	17
119	Metabolic considerations of drugs in the treatment of allergic diseases. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 1437-1452.	1.5	4
120	Dopamine receptor D3 (DRD3) gene rs6280 variant and risk for restless legs syndrome. Sleep Medicine, 2013, 14, 382-384.	0.8	16
121	Fused in Sarcoma (FUS) gene mutations are not a frequent cause of essential tremor in Europeans. Neurobiology of Aging, 2013, 34, 2441.e9-2441.e11.	1.5	22
122	MAPT gene rs1052553 variant is not associated with the risk for multiple sclerosis. Human Immunology, 2013, 74, 1705-1708.	1.2	4
123	Anti-Parkinson's disease drugs and pharmacogenetic considerations. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 859-874.	1.5	47
124	Update on genetics of essential tremor. Acta Neurologica Scandinavica, 2013, 128, 359-371.	1.0	41
125	Research Highlights: Highlights from the latest articles in essential tremor biomarkers and pharmacogenomics. Pharmacogenomics, 2013, 14, 1679-1682.	0.6	5
126	Use of Fourier-domain OCT to detect retinal nerve fiber layer degeneration in Parkinsonâ€™s disease patients. Eye, 2013, 27, 507-514.	1.1	93

#	Article	IF	Citations
127	Diagnostic ability of a new method for measuring haemoglobin levels in the optic nerve head in multiple sclerosis patients. British Journal of Ophthalmology, 2013, 97, 1543-1548.	2.1	15
128	Variability in histamine receptor genes HRH1, HRH2 and HRH4 in patients with hypersensitivity to NSAIDs. Pharmacogenomics, 2013, 14, 1871-1878.	0.6	18
129	No association of the SLC1A2 rs3794087 allele with risk for essential tremor in the Spanish population. Pharmacogenetics and Genomics, 2013, 23, 587-590.	0.7	22
130	Clarifying haplotype ambiguity of NAT2 in multi-national cohorts. Frontiers in Bioscience - Scholar, 2013, S5, 672-684.	0.8	10
131	Vitamin D3 Receptor (VDR) Gene rs2228570 (Fok1) and rs731236 (Taq1) Variants Are Not Associated with the Risk for Multiple Sclerosis: Results of a New Study and a Meta-Analysis. PLoS ONE, 2013, 8, e65487.	1.1	57
132	Influence of Vitamin D-Related Gene Polymorphisms (CYP27B and VDR) on the Response to Interferon/Ribavirin Therapy in Chronic Hepatitis C. PLoS ONE, 2013, 8, e74764.	1.1	36
133	Latest Perspectives in Genetic Risk Factors for Restless Legs Syndrome. European Neurological Review, 2013, 8, 90.	0.5	7
134	Hereditary Coproporphyria Associated with the Q306X Mutation in the Coproporphyrin Oxidase Gene Presenting with Acute Ataxia. Tremor and Other Hyperkinetic Movements, 2013, 3, .	1.1	1
135	FUS: a putative biomarker for essential tremor raised by whole-exome sequencing analyses. Pharmacogenomics, 2013, 14, 1680-1.	0.6	4
136	Genetic biomarkers of essential tremor: time to think outside of the box. Pharmacogenomics, 2013, 14, 1681-2.	0.6	2
137	The Diamine Oxidase Gene Is Associated with Hypersensitivity Response to Non-Steroidal Anti-Inflammatory Drugs. PLoS ONE, 2012, 7, e47571.	1.1	52
138	LINGO1 rs9652490 and rs11856808 are not associated with the risk of Parkinsonâ€™s disease: Results of a meta-analysis. Parkinsonism and Related Disorders, 2012, 18, 657-659.	1.1	7
139	Genetic variants of the arachidonic acid pathway in nonâ€steroidal antiâ€inflammatory drugâ€induced acute urticaria. Clinical and Experimental Allergy, 2012, 42, 1772-1781.	1.4	49
140	Polymorphism of the <i>TLR4</i> Gene Reduces the Risk of Hepatitis C Virus-Induced Hepatocellular Carcinoma. Oncology, 2012, 82, 35-40.	0.9	50
141	LINGO1 and risk for essential tremor: Results of a meta-analysis of rs9652490 and rs11856808. Journal of the Neurological Sciences, 2012, 317, 52-57.	0.3	39
142	Ability and Reproducibility of Fourier-Domain Optical Coherence Tomography to Detect Retinal Nerve Fiber Layer Atrophy in Parkinson's Disease. Ophthalmology, 2012, 119, 2161-2167.	2.5	107
143	Relation of IL28B Gene Polymorphism with Biochemical and Histological Features in Hepatitis C Virus-Induced Liver Disease. PLoS ONE, 2012, 7, e37998.	1.1	45
144	H1-MAPT and the Risk for Familial Essential Tremor. PLoS ONE, 2012, 7, e41581.	1.1	17

#	Article	IF	Citations
145	The Differential Effect of NAT2 Variant Alleles Permits Refinement in Phenotype Inference and Identifies a Very Slow Acetylation Genotype. PLoS ONE, 2012, 7, e44629.	1.1	44
146	Trends in Qualifying Biomarkers in Drug Safety. Consensus of the 2011 Meeting of the Spanish Society of Clinical Pharmacology. Frontiers in Pharmacology, 2012, 3, 2.	1.6	11
147	Frequencies of 23 Functionally Significant Variant Alleles Related with Metabolism of Antineoplastic Drugs in the Chilean Population: Comparison with Caucasian and Asian Populations. Frontiers in Genetics, 2012, 3, 229.	1.1	61
148	Toward a clinical practice guide in pharmacogenomics testing for functional polymorphisms of drug-metabolizing enzymes. Gene/drug pairs and barriers perceived in Spain. Frontiers in Genetics, 2012, 3, 273.	1.1	23
149	Analysis of the Functional Polymorphism in the Cytochrome P450 CYP2C8 Gene rs11572080 with Regard to Colorectal Cancer Risk. Frontiers in Genetics, 2012, 3, 278.	1.1	8
150	The relationship between Parkinson's disease and essential tremor: review of clinical, epidemiologic, genetic, neuroimaging and neuropathological data, and data on the presence of cardinal signs of parkinsonism in essential tremor. Tremor and Other Hyperkinetic Movements, 2012, 2, .	1.1	15
151	Assessment of nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 817-828.	1.5	48
152	Influence of age and gender in motor performance in healthy subjects. Journal of the Neurological Sciences, 2011, 302, 72-80.	0.3	62
153	DeterminaciÃ³n del polimorfismo de CYP2C9*2 y su relaciÃ³n con la farmacocinÃ©tica de acenocumarol en voluntarios sanos. Revista Chilena De CardiologÃ¤, 2011, 30, 218-224.	0.0	2
154	Gamma-aminobutyric acid GABRA4, GABRE, and GABRQ receptor polymorphisms and risk for essential tremor. Pharmacogenetics and Genomics, 2011, 21, 436-439.	0.7	28
155	A polymorphism located at an ATG transcription start site of the heme oxygenase-2 gene is associated with classical Parkinson's disease. Pharmacogenetics and Genomics, 2011, 21, 565-571.	0.7	18
156	Cytochrome P450 CYP2B6 genotypes and haplotypes in a Colombian population. Pharmacogenetics and Genomics, 2011, 21, 773-778.	0.7	14
157	Lack of association of LINGO1 rs9652490 and rs11856808 SNPs with familial essential tremor. European Journal of Neurology, 2011, 18, 1085-1089.	1.7	30
158	Gamma-aminobutyric acid (GABA) receptor rho (GABRR) polymorphisms and risk for essential tremor. Journal of Neurology, 2011, 258, 203-211.	1.8	28
159	LINGO1 gene analysis in Parkinson's disease phenotypes. Movement Disorders, 2011, 26, 722-727.	2.2	17
160	Paraoxonase 1 (PON1) polymorphisms and risk for migraine. Journal of Neurology, 2010, 257, 1482-1485.	1.8	17
161	Paraoxonase 1 Polymorphisms Are Not Related with the Risk for Multiple Sclerosis. NeuroMolecular Medicine, 2010, 12, 217-223.	1.8	17
162	Two common nonsynonymous paraoxonase 1 (PON1) gene polymorphisms and brain astrocytoma and meningioma. BMC Neurology, 2010, 10, 71.	0.8	23

#	Article	IF	Citations
163	Variability in ethanol biodisposition in whites is modulated by polymorphisms in theADH1BandADH1Cgenes. Hepatology, 2010, 51, 491-500.	3.6	36
164	Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury. Hepatology, 2010, 52, 303-312.	3.6	97
165	Histamineâ€Nâ€methyl transferase polymorphism and risk for multiple sclerosis. European Journal of Neurology, 2010, 17, 335-338.	1.7	16
166	Paraoxonase 1 (PON1) polymorphisms and risk for essential tremor. European Journal of Neurology, 2010, 17, 879-881.	1.7	9
167	Dopamine receptor 3(DRD3) polymorphism and risk for migraine. European Journal of Neurology, 2010, 17, 1220-1223.	1.7	13
168	Alcohol Dehydrogenase 2 Genotype and Risk for Migraine. Headache, 2010, 50, 85-91.	1.8	25
169	Variability of the <scp>L</scp>â€Histidine decarboxylase gene in allergic rhinitis. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 1576-1584.	2.7	27
170	Efficacy and Tolerability of Imiquimod 5% Cream to Treat Periocular Basal Cell Carcinomas. Journal of Ocular Pharmacology and Therapeutics, 2010, 26, 373-379.	0.6	26
171	Pharmacogenomics in Aspirin Intolerance. Current Drug Metabolism, 2009, 10, 998-1008.	0.7	58
172	Polymorphic Drug Metabolism in Anaesthesia. Current Drug Metabolism, 2009, 10, 236-246.	0.7	78
173	Reply:. Hepatology, 2009, 49, 1777-1779.	3.6	0
174	Dopamine receptor D3 (DRD3) genotype and allelic variants and risk for essential tremor. Movement Disorders, 2009, 24, 1910-1915.	2.2	24
175	Histamine pharmacogenomics. Pharmacogenomics, 2009, 10, 867-883.	0.6	67
176	Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: Is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 607-620.	1.5	92
177	Analysis of a non-synonymous single nucleotide polymorphism of the human diamine oxidase gene (ref.) Tj ETQq1 1 0.784314 rgBT /O 44, 1207-1212.	0.6	5
178	Pharmacogenomics in Drug Induced Liver Injury. Current Drug Metabolism, 2009, 10, 956-970.	0.7	70
179	Nonsynonymous Polymorphisms of Histamine-Metabolising Enzymes in Patients with Parkinsonâ€™s Disease. NeuroMolecular Medicine, 2008, 10, 10-16.	1.8	31
180	The Nonsynonymous Thr105Ile Polymorphism of the Histamine N-Methyltransferase is Associated to the Risk of Developing Essential Tremor. NeuroMolecular Medicine, 2008, 10, 356-361.	1.8	23

#	Article	IF	Citations
181	Genetic variability of histamine receptors in patients with Parkinson's disease. BMC Medical Genetics, 2008, 9, 15.	2.1	26
182	GlutathioneS-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology, 2008, 48, 588-596.	3.6	181
183	Response to the Letter to the Editor regarding â€œImproved analytical sensitivity reveals the occurrence of gender-related variability in diamine oxidase enzyme activity in healthy individualsâ€. Clinical Biochemistry, 2008, 41, 1260-1261.	0.8	0
184	Histamineâ€Nâ€Methyl Transferase Polymorphism and Risk for Migraine. Headache, 2008, 48, 1343-1348.	1.8	23
185	Glutathione-S-transferase P1 polymorphism and risk for essential tremor. European Journal of Neurology, 2008, 15, 234-238.	1.7	18
186	Unraveling Ambiguous NAT2 Genotyping Data. Clinical Chemistry, 2008, 54, 1390-1394.	1.5	62
187	Interethnic and Intraethnic Variability of NAT2 Single Nucleotide Polymorphisms. Current Drug Metabolism, 2008, 9, 487-497.	0.7	84
188	Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding. Pharmacogenetics and Genomics, 2008, 18, 37-43.	0.7	64
189	GSTT1andGSTM1Null Genotypes May Facilitate Hepatitis C Virus Infection Becoming Chronic. Journal of Infectious Diseases, 2007, 195, 1320-1323.	1.9	19
190	Glutathione S-transferases Ï€1, Î±1 and Âµ3 genetic polymorphisms and the risk of hepatocellular carcinoma in humans. Pharmacogenomics, 2007, 8, 895-899.	0.6	13
191	Effect of Common NAT2 Variant Alleles in the Acetylation of the Major Clonazepam Metabolite, 7-minoclonazepam. Drug Metabolism Letters, 2007, 1, 3-5.	0.5	21
192	Genetic variability of human diamine oxidase: occurrence of three nonsynonymous polymorphisms and study of their effect on serum enzyme activity. Pharmacogenetics and Genomics, 2007, 17, 687-693.	0.7	41
193	Cytochrome P450 CYP2C9 Polymorphism and NSAID-Related Acute Gastrointestinal Bleeding. Gastroenterology, 2007, 133, 2071-2072.	0.6	9
194	Improved analytical sensitivity reveals the occurrence of gender-related variability in diamine oxidase enzyme activity in healthy individuals. Clinical Biochemistry, 2007, 40, 1339-1341.	0.8	30
195	Polymorphisms of histamine-metabolizing enzymes and clinical manifestations of asthma and allergic rhinitis. Clinical and Experimental Allergy, 2007, 37, 1175-1182.	1.4	54
196	Genetic variability in CYP3A4 and CYP3A5in primary liver, gastric and colorectal cancer patients. BMC Cancer, 2007, 7, 118.	1.1	19
197	Changes at the CYP2C locus and disruption of CYP2C8/9 linkage disequilibrium in patients with essential tremor. NeuroMolecular Medicine, 2007, 9, 195-204.	1.8	16
198	Alcohol Dehydrogenase 2 Genotype and Allelic Variants Are Not Associated With the Risk for Essential Tremor. Clinical Neuropharmacology, 2007, 30, 196-200.	0.2	19

#	Article	IF	Citations
199	Changes at the CYP2C locus and disruption of CYP2C8/9 linkage disequilibrium in patients with essential tremor. NeuroMolecular Medicine, 2007, 9, 195-204.	1.8	1
200	Acquired resistance to the anticancer drug paclitaxel is associated with induction of cytochrome P450 2C8. Pharmacogenomics, 2006, 7, 575-585.	0.6	43
201	Interethnic and Intraethnic Variability of CYP2C8 and CYP2C9 Polymorphisms in Healthy Individuals. Molecular Diagnosis and Therapy, 2006, 10, 29-40.	1.6	156
202	Glutathione S-transferase M1 and T1 genetic polymorphisms are not related to the risk of hepatocellular carcinoma: A study in the Spanish population. European Journal of Cancer, 2006, 42, 73-77.	1.3	22
203	Increased frequency of rapid acetylator genotypes in patients with brain astrocytoma and meningioma. Acta Neurologica Scandinavica, 2006, 113, 322-326.	1.0	9
204	CYP2C19 Polymorphism and Risk for Essential Tremor. European Neurology, 2006, 56, 119-123.	0.6	29
205	GlutathioneS-transferases Î¼1, Î¸1, Ï€1, Î±1 and Î¼3 genetic polymorphisms and the risk of colorectal and gastric cancers in humans. Pharmacogenomics, 2006, 7, 711-718.	0.6	79
206	Severity of ulcerative colitis is associated with a polymorphism at diamine oxidase gene but not at histamine N-methyltransferase gene. World Journal of Gastroenterology, 2006, 12, 615.	1.4	38
207	The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects. British Journal of Clinical Pharmacology, 2005, 59, 62-68.	1.1	109
208	Cytochrome P450 Gene Polymorphisms and Variability in Response to NSAIDs. Clinical Research and Regulatory Affairs, 2005, 22, 57-81.	2.1	17
209	Polymorphisms of the glutathione S-transferases mu-1 (GSTM1) and theta-1 (GSTT1) and the risk of advanced alcoholic liver disease. Scandinavian Journal of Gastroenterology, 2005, 40, 348-353.	0.6	56
210	Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. British Journal of Pharmacology, 2004, 141, 205-208.	2.7	117
211	Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms*1. Clinical Pharmacology and Therapeutics, 2004, 76, 119-127.	2.3	159
212	Influence of cytochrome P450 CYP2C9 genotypes in lung cancer risk. Cancer Letters, 2002, 180, 41-46.	3.2	23
213	Inhibition of oxidative stress produced by plasma membrane NADH oxidase delays low-potassium-induced apoptosis of cerebellar granule cells. Journal of Neurochemistry, 2002, 82, 705-715.	2.1	45
214	Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy. British Journal of Cancer, 2002, 87, 681-686.	2.9	57
215	CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. Clinical Pharmacology and Therapeutics, 2002, 71, 196-204.	2.3	120
216	High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population.. European Journal of Clinical Pharmacology, 2001, 57, 47-49.	0.8	79

#	Article	IF	Citations
217	Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk. Carcinogenesis, 2001, 22, 1323-1326.	1.3	47
218	The Expression of Plasma Membrane Ca2+ Pump Isoforms in Cerebellar Granule Neurons Is Modulated by Ca2+. Journal of Biological Chemistry, 1999, 274, 1667-1676.	1.6	100
219	Hypothalamic Hypophyseal Inhibitory Factor (HHIF) Increases Intrasynaptosomal Free Calcium Concentration. Hypertension, 1997, 29, 1337-1343.	1.3	1
220	Rate of Na+/Ca2+ exchange across the plasma membrane of synaptosomes measured using the fluorescence of chlorotetracycline. Implications to calcium homeostasis in synaptic terminals. Biochimica Et Biophysica Acta - Biomembranes, 1996, 1280, 257-264.	1.4	10
221	Inactivation of ecto-ATPase activity of rat brain synaptosomes. Biochimica Et Biophysica Acta - Biomembranes, 1996, 1283, 51-59.	1.4	15
222	The plasma membrane calcium pump: Recent developments and future perspectives. Experientia, 1996, 52, 1091-1100.	1.2	80
223	Modulation of the Ca 2+,Mg2+-ATPase of sarcoplasmic reticulum by the hypothalamic hypophyseal inhibitory factor. Biochimica Et Biophysica Acta - Bioenergetics, 1995, 1232, 217-224.	0.5	1
224	Intrasynaptosomal Free Mg²⁺ Concentration Measured with the Fluorescent Indicator Magâ€Furaâ€2: Modulation by Na⁺ Gradient and by Extrasynaptosomal ATP. Journal of Neurochemistry, 1995, 65, 2757-2764.	2.1	9
225	Modulation of the Ca 2+ Pump by the Hypothalamic-Hypophysary Inhibitory Factor. Hypertension, 1995, 25, 365-371.	1.3	2
226	Fluorescence energy transfer as a tool to locate functional sites in membrane proteins. Biochemical Society Transactions, 1994, 22, 784-788.	1.6	14
227	Properties of the Purified Hypothalamic Pituitary NA/K-ATPase Inhibitor. Journal of Cardiovascular Pharmacology, 1993, 22, S32-S34.	0.8	14
228	Modulation of the Ca2+,Mg2+-ATPase Activity of Synaptosomal Plasma Membrane by the Local Anesthetics Dibucaine and Lidocaine. Journal of Neurochemistry, 1990, 54, 1238-1246.	2.1	33
229	Modulation of Calcium Fluxes Across Synaptosomal Plasma Membrane by Local Anesthetics. Journal of Neurochemistry, 1990, 55, 370-378.	2.1	28
230	Modulation of (Ca2+ + Mg2+)-ATPases and Ca2+ fluxes through the plasma membrane of synaptosomes and sarcoplasmic reticulum by local anaesthetics. Biochemical Society Transactions, 1989, 17, 960-962.	1.6	6
231	Local Anesthetics Inhibit the Ca²⁺,Mg²⁺â€ATPase Activity of Rat Brain Synaptosomes. Journal of Neurochemistry, 1986, 47, 668-672.	2.1	31